<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">33620810</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK567733</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-128148">Laryngeal Botulinum Toxin Injection</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Biello</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tripler Army Medical Center</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volner</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Tripler Army Medical Center</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Sungjin A.</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Uniformed Services University of the Health Sciences, Tripler Army Medical Center</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Botulinum toxin is a neurotoxin produced from <i>Clostridium botulinum</i>, an anaerobic, gram-positive bacteria. Injection of botulinum toxin into a muscle temporarily denervates the targeted muscle. It also reduces secretory function when injected into a gland. Although botulinum toxin has traditionally been utilized in facial cosmetics/aesthetics to address rhytids, it is also a useful tool in addressing laryngeal pathology. Before introducing botulinum toxin, laryngeal dystonia was historically treated with psychotherapy and speech therapy, both of which were significantly limited in their effectiveness for this disorder. The use of botulinum toxin has been described in the management of both adductor and abductor laryngeal dystonia/spasmodic dysphonia (SD), vocal tremor, vocal process granuloma, and cricopharyngeal muscle dysfunction. By selectively denervating targeted laryngeal musculature, the surgeon can strategically address these pathologies.  The vast majority (65%) of SD patients are female, with an average age of onset of 45 years. The prevalence of SD is 1 per 100,000. In adductor spasmodic dysphonia (ADSD), the thyroarytenoid (TA) muscle is targeted for chemodenervation. Botulinum toxin chemodenervation, initiated in the 1980s by Blitzer and colleagues, is now considered the gold standard for the treatment of ADSD.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s3">Anatomy and Physiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s4">Indications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s5">Contraindications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s6">Equipment</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s7">Personnel</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s8">Preparation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s9">Technique</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s10">Complications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s11">Clinical Significance</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s12">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s13">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-128148" sec="article-128148.s14">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>5</Month><Day>1</Day></ContributionDate><ReferenceList><Reference><Citation>Awan KH. The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions - An evidence based review. Saudi Pharm J. 2017 Jan;25(1):18-24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5310164</ArticleId><ArticleId IdType="pubmed">28223858</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhetri DK, Berke GS. Treatment of adductor spasmodic dysphonia with selective laryngeal adductor denervation and reinnervation surgery. Otolaryngol Clin North Am. 2006 Feb;39(1):101-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG. Spasmodic Dysphonia: A Review. Part 1: Pathogenic Factors. Otolaryngol Head Neck Surg. 2017 Oct;157(4):551-557.</Citation><ArticleIdList><ArticleId IdType="pubmed">28850801</ArticleId></ArticleIdList></Reference><Reference><Citation>Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005 Mar;63(1):180-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15830090</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel PN, Kabagambe EK, Starkweather JC, Keller M, Gamsarian V, Lee J, Kulkarni V, Garrett CG, Francis DO. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor. JAMA Otolaryngol Head Neck Surg. 2018 Apr 01;144(4):293-299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876916</ArticleId><ArticleId IdType="pubmed">29423509</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaney KO, Rinaldo A, Ferlito A. Vocal process granuloma of the larynx-recognition, differential diagnosis and treatment. Oral Oncol. 2005 Aug;41(7):666-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023983</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapaniemi JJ, Laurikainen EA, Pulkkinen J, Marttila RJ. Botulinum toxin in the treatment of cricopharyngeal dysphagia. Dysphagia. 2001 Summer;16(3):171-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11453562</ArticleId></ArticleIdList></Reference><Reference><Citation>Small R. Botulinum toxin injection for facial wrinkles. Am Fam Physician. 2014 Aug 01;90(3):168-75.</Citation><ArticleIdList><ArticleId IdType="pubmed">25077722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaderbay A, Righini CA, Castellanos PF, Atallah I. Office-based endoscopic botulinum toxin injection in laryngeal movement disorders. Eur Ann Otorhinolaryngol Head Neck Dis. 2018 Jun;135(3):205-207.</Citation><ArticleIdList><ArticleId IdType="pubmed">29661610</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink DS, Achkar J, Franco RA, Song PC. Interarytenoid botulinum toxin injection for recalcitrant vocal process granuloma. Laryngoscope. 2013 Dec;123(12):3084-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24115127</ArticleId></ArticleIdList></Reference><Reference><Citation>Yershov D, Partridge R. Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia. Prague Med Rep. 2020;121(2):114-117.</Citation><ArticleIdList><ArticleId IdType="pubmed">32553095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdan AL, Khalifee E, Jaffal H, Ghanem A. Interarytenoid botulinum toxin A injection for the treatment of vocal process granuloma. J Laryngol Otol. 2019 Dec;133(12):1041-1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">31711548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyberg-Åhlander V, Rydell R, Fredlund P, Magnusson C, Wilén S. Prevalence of Voice Disorders in the General Population, Based on the Stockholm Public Health Cohort. J Voice. 2019 Nov;33(6):900-905.</Citation><ArticleIdList><ArticleId IdType="pubmed">30126692</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33620810</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
